ConductScience.org, home

Trial · NCT07904325

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryRadial artery flow-mediated dilation (FMD)Single study visit (Day 1)Percentage change in radial artery diameter
PrimaryRadial artery low-flow mediated constriction (L-FMC)Single study visit (Day 1)Percentage change in radial artery diameter
SecondaryCarotid artery reactivity (CAR)Single study visit (Day 1)
Percentage change in common carotid artery diameter from 1 minute of rest to the peak response during 3 minutes of hand immersion in iced water (4 degrees C or below; cold pressor test), measured by high-resolution ultrasound. Compared between adults with CF and age/sex matched healthy controls.
SecondaryCarotid intima-media thickness (IMT)Single study visit (Day 1)
Mean common carotid artery intima-media thickness (mm), measured bilaterally by B-mode ultrasound approximately 1 cm proximal to the carotid bulb in anterior, lateral and posterior views. Compared between adults with CF and age/sex matched healthy controls.
SecondaryCerebral neurovascular couplingSingle study visit (Day 1)
Change in cerebral artery mean blood flow velocity (transcranial Doppler) in response to a standard visual stimulation protocol (alternating 30-second eyes open and eyes closed periods), expressed as percentage increase from eyes-closed baseline. Compared between adults with CF and age/sex matched healthy controls.
SecondaryCerebral autoregulation (spontaneous and dynamic)Single study visit (Day 1)
Relationship between beat-to-beat blood pressure and cerebral artery mean blood flow velocity (transcranial Doppler), assessed during 10 minutes of supine rest (spontaneous) and during 5 minutes of repeated 10-second squat-stand manoeuvres (dynamic), with continuous ECG and end-tidal gas monitoring. Compared between adults with CF and age/sex matched healthy controls.
SecondaryBaroreflex sensitivity and baroreflex effectiveness indexSingle study visit (Day 1)
Cardiac baroreflex sensitivity (ms/mmHg) and baroreflex effectiveness index derived from continuous ECG and beat-to-beat finger blood pressure, during 10 minutes of supine rest (spontaneous) and during 5 minutes of repeated 10-second squat-stand manoeuvres (dynamic). Compared between adults with CF and age/sex matched healthy controls.
SecondaryCognitive functionSingle study visit (Day 1)
Cognitive performance assessed by the Standardised Mini-Mental State Examination (total score 0 to 30; higher scores indicate better cognitive function), the Wisconsin Card Sorting Task (e.g. categories completed and perseverative errors) and a Lexical Decision Task (accuracy and reaction time). Compared between adults with CF and age/sex matched healthy controls, and examined for association with neurovascular coupling.
SecondaryAnxiety and depression (Hospital Anxiety and Depression Scale)Single study visit (Day 1)
Hospital Anxiety and Depression Scale anxiety and depression subscale scores (each 0 to 21; higher scores indicate more severe symptoms). Compared between adults with CF and age/sex matched healthy controls, and examined for association with neurovascular coupling.
OtherHealth-related quality of lifeSingle study visit (Day 1)
Health-related quality of life assessed EQ-5D-5L (index value and visual analogue scale 0 to 100; higher scores indicate better health). Compared between adults with CF and age/sex matched healthy controls.
OtherAssociation between inflammatory/oxidative stress markers and vascular and autonomic function in CFSingle study visit (Day 1)
In participants with CF, regression analysis of the association between blood markers of inflammation and oxidative stress and measures of peripheral vascular function (FMD, L-FMC, carotid artery reactivity), cerebrovascular function (neurovascular coupling, cerebral autoregulation) and baroreflex function.
OtherHealth-related quality of lifeSingle study visit (Day 1)Health-related quality of life assessed by the RAND 36-Item Health Survey. Compared between adults with CF and age/sex matched healthy controls.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07904325/registered